Pharmaceuticals company Laurus Labs announced Q1FY27 results Consolidated Financial Highlights: Total Revenue from operations for Q1FY27 stood at Rs 2,026.31 crore, reflecting a growth of 11.85% QoQ from Rs 1,811.57 crore in Q4FY26 and an increase of 29.10% YoY compared to Rs 1,569.57 crore in Q1FY26. Total Income for the quarter was Rs 2,035.49 crore, showing an 11.63% increase from Rs 1,823.37 crore in Q4FY26 and a 28.83% growth from Rs 1,580.00 crore in Q1FY26. Profit Before Tax (PBT) for Q1FY27 was reported at Rs 481.36 crore, marking a growth of 33.20% QoQ from Rs 361.37 crore in Q4FY26 and a substantial rise of 114.68% YoY from Rs 224.22 crore in Q1FY26. Net Profit for the period (after share of profit/loss from associates and joint venture) reached Rs 362.07 crore, representing a 28.35% QoQ increase from Rs 282.09 crore in Q4FY26 and a 123.94% YoY increase from Rs 161.68 crore in Q1FY26. Total Comprehensive Income for Q1FY27 was Rs 359.86 crore, compared to Rs 284.17 crore in Q4FY26 and Rs 160.97 crore in Q1FY26. Basic Earnings Per Share (EPS) for the quarter improved to Rs 6.81, up from Rs 5.17 in Q4FY26 and Rs 3.02 in Q1FY26. Standalone Financial Highlights: Revenue from operations for Q1FY27 was Rs 1,757.16 crore, a growth of 11.19% QoQ from Rs 1,580.30 crore in Q4FY26 and a 22.64% YoY increase from Rs 1,432.75 crore in Q1FY26. Total Income for the quarter stood at Rs 1,777.23 crore, up 11.54% from Rs 1,593.39 crore in Q4FY26 and 22.21% from Rs 1,454.27 crore in Q1FY26. Profit Before Tax (PBT) reached Rs 388.17 crore in Q1FY27, reflecting an increase of 49.66% QoQ from Rs 259.37 crore in Q4FY26 and an 83.58% YoY growth from Rs 211.44 crore in Q1FY26. Net Profit for the period was Rs 289.96 crore, showing a significant QoQ growth of 51.19% from Rs 191.79 crore in Q4FY26 and an 83.59% YoY increase from Rs 157.94 crore in Q1FY26. Total Comprehensive Income for the standalone entity was Rs 288.15 crore in Q1FY27, compared to Rs 196.79 crore in Q4FY26 and Rs 157.75 crore in Q1FY26. Basic Earnings Per Share (EPS) for the standalone business was Rs 5.37 for Q1FY27, against Rs 3.55 in Q4FY26 and Rs 2.93 in Q1FY26. Business Highlights: Scheme of Arrangement: The Board has approved a Composite Scheme of Arrangement for the demerger of the Identified Business Undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited and the amalgamation of the Remaining Undertaking of Laurus Synthesis Private Limited with the Company. The implementation is subject to approvals from the NCLT and other authorities, with an appointed date of April 01, 2026. ESOP Allotment: During Q1FY27, the Company allotted 393,001 equity shares of Rs 2 each following the exercise of stock options by employees under the Employee Stock Option Scheme. Strategic Investments: The company previously invested Rs 35 crore into Laurus Bio Private Limited and contributed Rs 49 crore as capital to the KRKA Pharma Private Limited joint venture (49% stake) during the year ended March 31, 2026 (FY26). Subsidiary Performance: Six subsidiaries (including step-down subsidiaries) contributed a total revenue of Rs 177.14 crore and a total net loss after tax of Rs 5.96 crore to the consolidated results for Q1FY27. Result PDF